東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back to Search results for [ null ]

Switch To: Labeled | MARC Mode | ISBD

Long Term Chemotherapy Treatment Ind...

Yoosuf, Zeenath Safira Khaja Mohamed.

Linked to FindBook

Google Book

Amazon

博客來

Long Term Chemotherapy Treatment Induces a Dual Immune Resistance in Colorectal Cancer Cells.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Long Term Chemotherapy Treatment Induces a Dual Immune Resistance in Colorectal Cancer Cells./
Author:	Yoosuf, Zeenath Safira Khaja Mohamed.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
Description:	106 p.
Notes:	Source: Masters Abstracts International, Volume: 81-03.
Contained By:	Masters Abstracts International81-03.
Subject:	Health sciences. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22589960
ISBN:	9781088374733

Long Term Chemotherapy Treatment Induces a Dual Immune Resistance in Colorectal Cancer Cells.
Yoosuf, Zeenath Safira Khaja Mohamed.

Long Term Chemotherapy Treatment Induces a Dual Immune Resistance in Colorectal Cancer Cells. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 106 p.

Source: Masters Abstracts International, Volume: 81-03.

Thesis (M.S.)--Hamad Bin Khalifa University (Qatar), 2019.

This item is not available from ProQuest Dissertations & Theses.

Colorectal Cancer (CRC) presents a substantial health burden globally, especially that its prevalence is escalating at an alarming rate. Current therapeutic interventions impart limited efficacy in the patient cure, specifically in progressing metastatic tumors. While recent advancements in immunotherapy have accomplished therapeutic benefit in microsatellite unstable (MSI) CRC, a wider cohort of microsatellite stable (MSS) tumor patients who predominantly present a non-inflamed immune cold phenotype, pose a major clinical challenge. In this context, it would be beneficial to escalate the therapeutic potential of existing conventional chemotherapeutic treatments used in CRC. The study aims to screen the expression of High Mobility Group Box Protein (HMGB1), an immunogenic cell death marker, and Programmed Death Ligand 1 (PD-L1), an immune checkpoint across HT-29, HCT 116, DLD-1, SW480, SW620 and LoVo CRC cell lines upon treatment with 5-Fluorouracil (5-Fu) and Oxaliplatin (Oxp). The cell lines were observed with a maximum cytotoxic response at 72 hours of treatment and the doses of 5µM and 50µM for 5-Fu, and, 5µM and 30µM for Oxp were chosen. HMGB1 expression was analyzed in the cultured cell supernatant and cell lysate of the treated cell lines by using ELISA and western blot analysis, respectively. Despite an inconsistent pattern of expression in the analyzed cell lines, all of them except HT-29 showed a decrease in HMGB1 expression especially at the higher concentration of the drugs. HMGB1 expression was also analyzed in CRC patient plasma samples, where a significant upregulation was observed in the patients as compared to healthy controls. 20 CRC Patients were stratified based on their therapeutic intervention of 5-Fu combinations, FOLFOX and FOLFIRI. Decrease of HMGB1 was seen in the treated patients as compared to non-treated CRC patients though the effect was void of significance. PD-L1 expression was initially analyzed using flow cytometry and further validated with western blot analysis. DLD-1, HCT 116 and HT-29 showed high PD-L1 induction, an effect that was more evident with 5-Fluorouracil than in Oxaliplatin. LoVo exhibited slight PD-L1 induction upon treatment with 5-Fu. The decline of an immunogenic cell death marker and the induction of an immune checkpoint molecule suggests a dual resistance mechanism promoted by the tumors. A combinatorial approach of the cytotoxic agents with immune checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 could provide durable therapeutic efficiency in CRC patients.

ISBN: 9781088374733Subjects--Topical Terms:

3168359
Health sciences.

Long Term Chemotherapy Treatment Induces a Dual Immune Resistance in Colorectal Cancer Cells.
LDR:03639nmm a2200313 4500 001 2267614
005 20200724103015.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781088374733
035 $a (MiAaPQ)AAI22589960
035 $a AAI22589960
040 $a MiAaPQ $c MiAaPQ
100 1 $a Yoosuf, Zeenath Safira Khaja Mohamed. $3 3544871
245 1 0 $a Long Term Chemotherapy Treatment Induces a Dual Immune Resistance in Colorectal Cancer Cells.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 106 p.
500 $a Source: Masters Abstracts International, Volume: 81-03.
500 $a Advisor: Dermime, Said;Horn, Henning.
502 $a Thesis (M.S.)--Hamad Bin Khalifa University (Qatar), 2019.
506 $a This item is not available from ProQuest Dissertations & Theses.
506 $a This item must not be sold to any third party vendors.
520 $a Colorectal Cancer (CRC) presents a substantial health burden globally, especially that its prevalence is escalating at an alarming rate. Current therapeutic interventions impart limited efficacy in the patient cure, specifically in progressing metastatic tumors. While recent advancements in immunotherapy have accomplished therapeutic benefit in microsatellite unstable (MSI) CRC, a wider cohort of microsatellite stable (MSS) tumor patients who predominantly present a non-inflamed immune cold phenotype, pose a major clinical challenge. In this context, it would be beneficial to escalate the therapeutic potential of existing conventional chemotherapeutic treatments used in CRC. The study aims to screen the expression of High Mobility Group Box Protein (HMGB1), an immunogenic cell death marker, and Programmed Death Ligand 1 (PD-L1), an immune checkpoint across HT-29, HCT 116, DLD-1, SW480, SW620 and LoVo CRC cell lines upon treatment with 5-Fluorouracil (5-Fu) and Oxaliplatin (Oxp). The cell lines were observed with a maximum cytotoxic response at 72 hours of treatment and the doses of 5µM and 50µM for 5-Fu, and, 5µM and 30µM for Oxp were chosen. HMGB1 expression was analyzed in the cultured cell supernatant and cell lysate of the treated cell lines by using ELISA and western blot analysis, respectively. Despite an inconsistent pattern of expression in the analyzed cell lines, all of them except HT-29 showed a decrease in HMGB1 expression especially at the higher concentration of the drugs. HMGB1 expression was also analyzed in CRC patient plasma samples, where a significant upregulation was observed in the patients as compared to healthy controls. 20 CRC Patients were stratified based on their therapeutic intervention of 5-Fu combinations, FOLFOX and FOLFIRI. Decrease of HMGB1 was seen in the treated patients as compared to non-treated CRC patients though the effect was void of significance. PD-L1 expression was initially analyzed using flow cytometry and further validated with western blot analysis. DLD-1, HCT 116 and HT-29 showed high PD-L1 induction, an effect that was more evident with 5-Fluorouracil than in Oxaliplatin. LoVo exhibited slight PD-L1 induction upon treatment with 5-Fu. The decline of an immunogenic cell death marker and the induction of an immune checkpoint molecule suggests a dual resistance mechanism promoted by the tumors. A combinatorial approach of the cytotoxic agents with immune checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 could provide durable therapeutic efficiency in CRC patients.
590 $a School code: 1931.
650 4 $a Health sciences. $3 3168359
650 4 $a Oncology. $3 751006
690 $a 0566
690 $a 0992
710 2 $a Hamad Bin Khalifa University (Qatar). $b Health and Life Sci. $3 3544857
773 0 $t Masters Abstracts International $g 81-03.
790 $a 1931
791 $a M.S.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22589960